0000000000125036

AUTHOR

Armin Szegedi

showing 55 related works from this author

Serotonergic polymorphisms in patients suffering from alcoholism, anxiety disorders and narcolepsy.

2001

Abstract 1. Alterations in the serotonergic neurotransmission have been frequently described for patients suffering from alcoholism, anxiety disorders and narcolepsy. 2. The authors tested for association of the 5-HT2A receptor polymorphism (T102C) and the intron 7 tryptophan hydroxylase (TPH) polymorphism (A218C) among 176 alcohol dependent patients, 35 patients with panic disorder, 50 patients with generalized anxiety disorder, 55 patients with narcolepsy and 87 healthy controls. 3. Allele and genotype frequencies of the 5-HT2A receptor polymorphism (T102C), the intron 7 TPH polymorphism (A218C) were almost similar between the patients suffering from alcohol dependence, panic disorder, ge…

AdultMalemedicine.medical_specialtyGeneralized anxiety disorderGenotypeNeurological disorderTryptophan HydroxylasePolymerase Chain ReactionInternal medicinemedicineHumansReceptor Serotonin 5-HT2ABiological PsychiatryPsychiatric geneticsAllelesNarcolepsyPharmacologySleep disorderPolymorphism GeneticPanic disorderAlcohol dependenceMiddle Agedmedicine.diseaseAnxiety DisordersAlcoholismEndocrinologyReceptors SerotoninAnxietyFemalemedicine.symptomPsychologyNarcolepsyProgress in neuro-psychopharmacologybiological psychiatry
researchProduct

Sex differences in allelic frequencies of the 5-HT2C Cys23Ser polymorphism in psychiatric patients and healthy volunteers: findings from an associati…

2000

Polymorphisms in the serotonergic system are believed to play a role in the etiology and treatment of different psychiatric illnesses. The 5-HT2C receptor gene is X-linked, with a frequent mutation at nucleotide 68 leading to a Ser-->Cys transition at amino acid 23. Recent studies have demonstrated an impaired function of 5-HT2C receptors and an increased production of the major noradrenergic metabolite 3-methoxy-4-hydroxyphenylethyleneglycol in the cerebrospinal fluid among the subjects carrying the Ser23 allele (Lappalainen et al., 1999). Biol. Psychiatry 46:821). We genotyped patients with alcohol dependence, panic disorder without agoraphobia, generalized anxiety disorder, narcolepsy an…

AdultMalemedicine.medical_specialtyX ChromosomeGeneralized anxiety disorderGene FrequencyReference ValuesGenotypeReceptor Serotonin 5-HT2CSerineGeneticsmedicineHumansCysteineAllelePsychiatryAllele frequencyAllelesBiological PsychiatryGenetics (clinical)NarcolepsySex CharacteristicsPolymorphism Geneticbusiness.industryMental DisordersPanic disorderAlcohol dependenceMiddle Agedmedicine.diseaseAnxiety DisordersAlcoholismPsychiatry and Mental healthAmino Acid SubstitutionReceptors SerotoninPanic DisorderFemalebusinessAgoraphobiaNarcolepsyPsychiatric Genetics
researchProduct

Carbohydrate-deficient transferrin (CDT) and HDL cholesterol (HDL) are highly correlated in male alcohol dependent patients.

2000

Background: Serum levels of total HDL cholesterol (HDL) are reportedly influenced by recent alcohol intake. We examined the correlation between HDL cholesterol and widely used markers of excessive alcohol intake, such as carbohydrate-deficient transferrin (CDT), γ-glutamyl-transferase (GGT), or mean corpuscular volume of erythrocytes (MCV), of which CDT is thought to be the most specific. Methods: Several serological markers [i.e., CDT, GGT, aspartate aminotransferase (ASAT), alanine aminotransferase (ALAT), MCV, and HDL] were determined in 100 actively drinking male patients with alcohol dependence (DSM-IV) and in 27 non-alcohol-dependent controls, according to routine procedures. Spearman…

AdultErythrocyte IndicesMalemedicine.medical_specialtyAdolescentCarbohydrate deficient transferrinMedicine (miscellaneous)AlcoholToxicologyStatistics Nonparametricchemistry.chemical_compoundInternal medicinemedicineHumansMean corpuscular volumeAgedchemistry.chemical_classificationEthanolmedicine.diagnostic_testbusiness.industryCholesterolAlcohol dependenceCholesterol HDLTransferringamma-GlutamyltransferaseMiddle AgedPsychiatry and Mental healthAlcoholismEndocrinologychemistryTransferrinToxicitylipids (amino acids peptides and proteins)businessBiomarkersAlcoholism, clinical and experimental research
researchProduct

Blood ethanol levels and adenylyl cyclase activity in lymphocytes of alcoholic patients

1999

Abstract Background: The adenylyl cyclase (AC) signal transduction pathway is a target of acute and chronic ethanol actions. This study examined whether AC activity in lymphocyte membranes of male alcoholic patients correlated with blood concentrations of ethanol. Methods: Patients ( n = 13; mean age: 40 ± 8 years) were studied on the day of admission (day 0) and 2 days later under detoxification. Moreover, 13 age-matched male healthy controls (mean age 40 ± 9 years) were included. Lymphocyte membranes were prepared by differential centrifugation whereby blood ethanol was washed out. As a measure of AC activity the formation of cyclic adenosine monophosphate (cAMP) from adenosine triphospha…

AdultMalemedicine.medical_specialtyLymphocyteStimulationGuanosine triphosphateAdenylyl cyclasechemistry.chemical_compoundAdenosine TriphosphateInternal medicineCyclic AMPmedicineHumansCyclic adenosine monophosphateLongitudinal StudiesLymphocytesBiological PsychiatryEthanolForskolinDose-Response Relationship DrugEthanolColforsinMiddle AgedAlcoholismmedicine.anatomical_structureEndocrinologychemistryCase-Control StudiesGuanosine TriphosphatePhosphorus RadioisotopesAdenosine triphosphateAdenylyl CyclasesSignal TransductionBiological Psychiatry
researchProduct

Seroquel (ICI 204 636), a putative "atypical" antipsychotic, in schizophrenia with positive symptomatology: results of an open clinical trial and cha…

1995

Preclinical data indicated that seroquel (ICI 204 636), a dibenzothiazepine with 5-HT2 and D2-like receptor antagonistic properties, might be an effective antipsychotic agent, causing fewer extrapyramidal side effects than typical neuroleptics. In the present study, 12 patients suffering from schizophrenia or schizophreniform disorder with predominantly positive symptomatology were treated in an open clinical trial for 4 weeks with seroquel at a maximum dosage of 750 mg/day. The drug was generally well tolerated, and virtually no adverse extrapyramidal side effects such as acute dystonia, parkinsonism or akathisia were observed. Total scores for BPRS (item score 0–6; baseline: 42.0±2.3; mea…

AdultMalePsychosismedicine.medical_specialtyDibenzothiazepinesTime Factorsmedicine.drug_classmedicine.medical_treatmentAtypical antipsychoticThyrotropinAkathisiaGastroenterologyQuetiapine FumarateAntipsychotic AgentInternal medicinemedicineHumansSchizophreniform disorderAntipsychoticAgedPharmacologyPsychiatric Status Rating ScalesParkinsonismElectroencephalographyMiddle Agedmedicine.diseaseProlactinTreatment OutcomeSchizophreniaAnesthesiaSchizophreniaFemaleSchizophrenic Psychologymedicine.symptomPsychologyAntipsychotic AgentsPsychopharmacology
researchProduct

A monoamine oxidase B gene variant and short-term antidepressant treatment response.

2007

Genetic differences among patients suffering from Major Depression are likely to contribute to interindividual differences in medication treatment response. Thus, the identification of gene variants affecting drug response is needed in order to be able to predict response to psychopharmacological drugs. This study analyzed a possible association of the common A644G single nucleotide polymorphism (SNP) within intron 13 of the monoamine oxidase B (MAOB) gene with antidepressant treatment response. The study population consisted of n = 102 patients with major depression (criteria of the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition; DSM-IV) participating in a randomized do…

OncologyAdultMalemedicine.medical_specialtyMirtazapineSingle-nucleotide polymorphismMirtazapineMianserinPharmacologyDouble-Blind MethodInternal medicinemedicineHumansMonoamine OxidaseBiological PsychiatryAllelesPharmacologyPsychiatric Status Rating ScalesDepressive Disorder MajorbiologyReverse Transcriptase Polymerase Chain ReactionDNAMiddle AgedMianserinParoxetineAntidepressive AgentsIntronsParoxetineData Interpretation Statisticalbiology.proteinAntidepressantFemaleMonoamine oxidase BMonoamine oxidase APsychologyPharmacogeneticsSelective Serotonin Reuptake Inhibitorsmedicine.drugProgress in neuro-psychopharmacologybiological psychiatry
researchProduct

Association analysis between variants of the interleukin-1beta and the interleukin-1 receptor antagonist gene and antidepressant treatment response i…

2008

André Tadic1, Dan Rujescu2, Matthias J Müller3, Ralf Kohnen4, Hans H. Stassen5, Armin Szegedi6, Norbert Dahmen11Department of Psychiatry, University of Mainz, Germany; 2Department of Psychiatry, University of Munich, Germany; 3Clinic for Psychiatry and Psychotherapy, Marburg-Sued, Germany, and Clinic for Psychiatry and Psychotherapy, Giessen, Germany; 4IMEREM, Nuernberg, Germany; 5Department of Psychiatry, University of Zurich, Switzerland; 6Organon, Roseland, NJ, USAAbstract: This study investigated the possible association of the interleukin-1 beta (IL-1β) C-511T promoter polymorphism and the interleukin-1 receptor antagonist (IL-1Ra) (86bp)n variable number o…

Neuropsychiatric Disease and Treatmentbusiness.industryMirtazapine610 Medicine & healthPharmacologyinterleukin-1 betaParoxetineantidepressive agentsPsychiatry and Mental healthVariable number tandem repeatInterleukin 1 receptor antagonistgenetic polymorphismsPolymorphism (computer science)10054 Clinic for Psychiatry Psychotherapy and Psychosomaticstreatment outcomeMedicineAntidepressantinterleukin-1 receptor antagonistmajor depressionbusinessBiological PsychiatryPharmacogeneticsOriginal ResearchGenetic associationmedicine.drug
researchProduct

Confirmation of association of the GABRA2 gene with alcohol dependence by subtype-specific analysis

2006

Objectives: Three recent studies revealed a haplotypic association of alcohol dependence with the gene encoding the {alpha}2 subunit of the {gamma}-aminobutyric acid type A (GABAA) receptor (GABRA2). The present study examined whether variation of the GABRA2 gene confers susceptibility to different subtypes of alcohol dependence in the German population. Methods: A total of 257 German alcohol-dependent patients and 88 healthy population controls were genotyped for six single-nucleotide polymorphisms covering the middle part and the 3′ end of GABRA2. Allelic, genotypic and haplotypic comparisons were done for subgroups of alcohol-dependent patients with a presumed high genetic load. Results:…

AdultMalemedicine.medical_specialtyGenotypeGene DosagePolymerase Chain ReactionPolymorphism Single NucleotideGastroenterologyLinkage DisequilibriumGABRG1Internal medicineGeneticsmedicineGenetic predispositionHumansGABRA2AlleleAllelesBiological PsychiatryGenetics (clinical)GeneticsbiologyHaplotypeAlcohol dependenceOdds ratioReceptors GABA-AGenetic loadAlcoholismPsychiatry and Mental healthHaplotypesCase-Control Studiesbiology.proteinFemalePsychiatric Genetics
researchProduct

SEQUENTIALLY ADJUSTED RANDOMIZATION TO FORCE BALANCE IN CONTROLLED TRIALS WITH UNKNOWN PREVALENCE OF COVARIATES: APPLICATION TO ALCOHOLISM RESEARCH

2005

In treatment outcome studies with small to medium sample sizes (n200), the balance of groups with regard to important factors, which sometimes occur at low prevalence, is indispensable for adequate interpretation. This study tested a method for use in clinical alcoholism research, an uncomplicated procedure for satisfactory randomization of patients to different treatments, taking into account relevant background variables.An easily applicable modification of Efron's biased coin method for the randomization of treatments within strata of unknown but low prevalence was compared with the original approach and alternative methods by computer simulation (10,000 runs). An application example for…

Restricted randomizationChi-Square DistributionRandomizationTreatment outcomeGeneral MedicineForce balanceClinical trialAlcoholismResearch DesignSample size determinationCovariateStatisticsPrevalenceHumansComputer SimulationSpecial casePsychologySocial psychologyRandomized Controlled Trials as TopicAlcohol and Alcoholism
researchProduct

Distigmine bromide induced acute psychotic disorder in a patient with multiple sclerosis.

2003

AbstractA female patient with multiple sclerosis (MS) suffered from an acute psychotic disorder after taking distigmine bromide for detrusor dysfunction. She showed a dramatic relief of her symptoms after the medication, distigmine bromide, was stopped. Distigmine is not supposed to penetrate the blood-brain barrier (BBB). However, in MS patients a leakage of the BBB could be hypothesized.

Malemedicine.medical_specialtyPsychosisMultiple Sclerosismedicine.medical_treatmentPyridinium CompoundsSuicide AttemptedBlood–brain barrierPsychoses Substance-InducedCentral nervous system diseasechemistry.chemical_compoundBromidemedicineHumansDistigminePsychiatric Status Rating ScalesChemotherapybusiness.industryMultiple sclerosisUrinary Retentionmedicine.diseasePathophysiologySurgeryPsychiatry and Mental healthmedicine.anatomical_structurechemistryParasympathomimeticsAnesthesiaFemalebusinessmedicine.drugEuropean psychiatry : the journal of the Association of European Psychiatrists
researchProduct

An overview of the clinical efficacy of mirtazapine

2002

Mirtazapine is at least as effective as the tricyclic antidepressants and trazodone in a wide range of patient subgroups including in- and out-patients with moderate to severe depression. It also appears to be at least as effective as the serotonin and noradrenaline reuptake inhibitor venlafaxine in the treatment of severely depressed melancholic patients. When compared with the selective serotonin reuptake inhibitors (SSRIs), mirtazapine shows a significantly earlier onset of action. Further analysis of a study comparing mirtazapine with the SSRI paroxetine indicated that early improvement was a highly sensitive predictor of later stable response for both drugs. The positive predictive val…

Time FactorsMirtazapineVenlafaxine HydrochlorideMirtazapineVenlafaxineMianserinAntidepressive Agents TricyclicPharmacologymedicineHumansPharmacology (medical)chemistry.chemical_classificationClinical Trials as TopicDepressive DisorderAdrenergic Uptake Inhibitorsbusiness.industryVenlafaxine HydrochlorideTrazodoneCyclohexanolsParoxetineAntidepressive AgentsParoxetinePsychiatry and Mental healthTreatment OutcomeNeurologychemistryNeurology (clinical)SerotoninOnset of actionbusinessSelective Serotonin Reuptake Inhibitorsmedicine.drugTricyclicHuman Psychopharmacology: Clinical and Experimental
researchProduct

Combination treatment with clozapine and paroxetine in schizophrenia: safety and tolerability data from a prospective open clinical trial.

1998

Clozapine is a drug with many side effects, some of them with potentially hazardous outcome (e.g. seizures, agranulocytosis), if not carefully monitored. It has been shown that the metabolism of clozapine may be affected by concomitant treatment with selective serotonin reuptake inhibitors (SSRIs), while there have been reports of improved efficacy on negative symptomatology of clozapine in combination with SSRIs. Therefore, this prospective open clinical trial was performed to investigate the safety and tolerability of the coadministration of clozapine and paroxetine under control of serum concentrations of clozapine and its metabolites and the effect of this combination treatment on psych…

AdultMalemedicine.medical_specialtyPharmacologyPharmacotherapyInternal medicinemedicineHumansPharmacology (medical)Prospective StudiesProspective cohort studyClozapineBiological PsychiatryClozapinePharmacologymedicine.diseaseParoxetineClinical trialPsychiatry and Mental healthParoxetineNeurologyTolerabilitySchizophreniaConcomitantSchizophreniaDrug Therapy CombinationFemaleNeurology (clinical)PsychologySelective Serotonin Reuptake Inhibitorsmedicine.drugAntipsychotic AgentsEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
researchProduct

Association study of suicidal behavior and affective disorders with a genetic polymorphism in ABCG1, a positional candidate on chromosome 21q22.3

2000

The gene that codes for the ABC transporter ABCG1 is located in a chromosomal susceptibility region (21q22.3) for affective disorders. Genetic variations in ABCG1 have been associated with affective disorders in Japanese males. In this study, we investigated the distribution of a G2457A polymorphism in patients with affective disorders, suicide attempters with various psychiatric diagnoses and healthy subjects. We initially found a trend towards a modest association with affective disorders in males (p = 0.046 for allele frequencies and p = 0.046 for AA versus GG). We conducted a replication study with independent patients and controls. There was no association with affective disorders, eit…

AdultGenetic MarkersMaleAdolescentGenotypeChromosomes Human Pair 21Positional candidatePoison controlBiologyChromosome (genetic algorithm)Polymorphism (computer science)GenotypemedicineHumansPharmacology (medical)AlleleAssociation (psychology)Allele frequencyAllelesBiological PsychiatryATP Binding Cassette Transporter Subfamily G Member 1AgedPharmacologyGeneticsPolymorphism GeneticSuicide attemptMood DisordersDNAMiddle Agedmedicine.diseaseSuicidePsychiatry and Mental healthNeuropsychology and Physiological PsychologyMood disordersNeurologyGenetic markerSuicidal behaviorATP-Binding Cassette TransportersFemaleNeurology (clinical)PsychologyEuropean Neuropsychopharmacology
researchProduct

Dose escalation vs. continued doses of paroxetine and maprotiline: a prospective study in depressed out-patients with inadequate treatment response

1997

In view of the fact that controlled prospective studies on the benefits of dose escalation of the selective serotonin re-uptake inhibitor (SSRI) paroxetine are lacking, we conducted a double-blind, randomized, parallel-group multicentre study designed to compare the possible benefits of dose escalation of paroxetine and maprotiline in patients suffering from major or minor depression according to modified Research Diagnostic Criteria (RDC) with inadequate treatment response. The study sample consisted of 544 out-patients with different degrees of severity of depression. Patients received either 20 mg paroxetine (n = 271) or 100 mg maprotiline (n = 273) for the first 3 weeks in a double-blin…

AdultMalePersonality InventoryResearch Diagnostic CriteriaDrug Administration Schedulelaw.inventionDouble-Blind MethodRandomized controlled triallawmedicineHumansProspective StudiesMaprotilineProspective cohort studyAdverse effectDepressive DisorderDose-Response Relationship DrugMiddle AgedParoxetineClinical trialParoxetinePsychiatry and Mental healthTreatment OutcomeMaprotilineAnesthesiaAntidepressive Agents Second-GenerationFemaleReuptake inhibitorPsychologymedicine.drugActa Psychiatrica Scandinavica
researchProduct

TheMAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression

2006

This study investigated the possible association of the MAOA T941G gene variant with differential antidepressant response to mirtazapine and/or paroxetine in 102 patients with major depression (DSM-IV criteria) participating in a randomized double-blind controlled clinical trial. Female mirtazapine-treated patients homozygous for the T-allele had a significantly faster and better treatment response than TG/GG-patients. In males, we failed to show an association between MAOA T941G gene variant and mirtazapine response. In the paroxetine-treated group, there were no significant differences in treatment response between MAOA T941G genotype groups. Time course of response and antidepressant eff…

AdultMaleOncologymedicine.medical_specialtyTime FactorsGenotypeGenetic LinkageMirtazapineMirtazapineMianserinPolymorphism Single NucleotideCellular and Molecular NeuroscienceDouble-Blind MethodGene FrequencyInternal medicineGenotypemedicineHumansAlleleMonoamine OxidaseGenotypingGenetics (clinical)Depressive Disorder MajorSex Characteristicsbusiness.industryMiddle AgedParoxetineAntidepressive AgentsClinical trialParoxetinePsychiatry and Mental healthTreatment OutcomeEndocrinologyAntidepressantFemalebusinessReuptake inhibitormedicine.drugAmerican Journal of Medical Genetics Part B: Neuropsychiatric Genetics
researchProduct

Pharmacokinetic Interactions of Clozapine With Selective Serotonin Reuptake Inhibitors

1998

Pharmacokinetic interactions of clozapine and its metabolites N-desmethylclozapine and clozapine N-oxide with the selective serotonin reuptake inhibitors (SSRIs) fluvoxamine and paroxetine were investigated in a prospective study in schizophrenic patients under steady-state conditions. Thirty patients were treated with clozapine at a target dose of 2.5 to 3.0 mg/kg of body weight. After gradual dose escalation, serum concentrations of clozapine and two metabolites were determined twice at 7-day intervals after steady-state conditions had been reached. Then, fluvoxamine (50 mg/day) or paroxetine (20 mg/day) was added in 16 and 14 patients, respectively. Serum concentrations of clozapine and …

AdultMaleAdolescentFluvoxaminePharmacologyPharmacokineticsmedicineHumansDrug InteractionsPharmacology (medical)Prospective StudiesProspective cohort studyClozapineClozapinebusiness.industrySmokingMiddle AgedDrug interactionParoxetineParoxetinePsychiatry and Mental healthFluvoxamineSchizophreniaFemaleSerotoninbusinessReuptake inhibitorSelective Serotonin Reuptake InhibitorsAntipsychotic Agentsmedicine.drugJournal of Clinical Psychopharmacology
researchProduct

Patterns of response to serotonergic antidepressants

2000

PharmacologyPsychiatry and Mental healthNeurologybusiness.industryMedicinePharmacology (medical)Neurology (clinical)SerotonergicbusinessNeuroscienceBiological PsychiatryEuropean Neuropsychopharmacology
researchProduct

Adenylyl cyclase activity is increased in younger, but decreased in older, alcoholic patients after detoxification.

2000

Acute and chronic administration of ethanol leads to alterations of the adenylyl cyclase (AC) signal transduction pathway. This study examined whether the formation of cAMP by AC in lymphocytes correlates with age in alcoholic patients and in healthy controls. Blood was drawn for preparation of lymphocyte membranes and for determination of basal, GTPgammaS-stimulated, and forskolin-stimulated AC activity from 68 actively drinking alcoholic patients (age, mean +/- SD: 45 +/- 10; range: 26-69 years) after ethanol detoxification. The patients' AC activity correlated negatively with age. In contrast, no effect of age was observed in the healthy controls (age, mean +/- SD: 42 +/- 11; range: 24-6…

AdultMalemedicine.medical_specialtyLymphocyteTemperanceStatistics NonparametricAdenylyl cyclaseBlood cellchemistry.chemical_compoundBasal (phylogenetics)Internal medicineDetoxificationMedicineHumansLymphocytesAgedEthanolbusiness.industryCase-control studyAge FactorsGeneral MedicineMiddle AgedAlcoholismmedicine.anatomical_structureEndocrinologychemistryCase-Control StudiesToxicitybusinessAdenylyl CyclasesAlcohol and alcoholism (Oxford, Oxfordshire)
researchProduct

Early improvement under mirtazapine and paroxetine predicts later stable response with high sensitivity in patients with major depression

2001

Pharmacologymedicine.medical_specialtybusiness.industryMirtazapineParoxetineGastroenterologyPsychiatry and Mental healthNeurologyInternal medicinemedicinePharmacology (medical)In patientNeurology (clinical)Sensitivity (control systems)businessBiological PsychiatryDepression (differential diagnoses)medicine.drugEuropean Neuropsychopharmacology
researchProduct

Evaluation of standardized rater training for the Positive and Negative Syndrome Scale (PANSS)

1998

The Positive and Negative Syndrome Scale (PANSS) is employed increasingly for the evaluation of therapeutic outcome in studies on schizophrenia. Rater training is important to improve the concordance and accuracy of ratings; however, there are no established guidelines for carrying out such training. We conducted rater training, under clinical conditions, of psychiatrists and clinical psychologists who were rather unfamiliar with the PANSS. Based on videotapes of PANSS interviews, all participants were trained during five successive standardized weekly sessions. The results were analyzed with respect to conventional criteria of concordance with standard expert ratings and interrater reliabi…

AdultMalePsychiatric Status Rating ScalesPositive and Negative Syndrome ScalePsychometricsConcordanceeducationMiddle AgedRater trainingmedicine.diseasePsychiatry and Mental healthInter-rater reliabilityTreatment OutcomeEvaluation Studies as TopicSchizophreniaTraining outcomeSchizophreniamedicineHumansFemalePsychologyBiological PsychiatryPsychopathologyClinical psychologySchizophrenia Research
researchProduct

Reliability and validity of the German version of the European Addiction Severity Index (EuropASI).

2001

This study provides data on the psychometric characteristics of the German version of the European Addiction Severity Index (EuropASI). The ASI is a frequently used clinical and research instrument that measures problem severity among people with substance dependence.The German ASI was used in a sample of 112 consecutively admitted male psychiatric inpatients seeking treatment for severe alcohol problems. The conceptual structure of the German ASI subscales was investigated by analyzing the intercorrelations of the severity ratings and composite scores. Internal consistency, interrater reliability and concurrent validity in terms of correlations with other assessment instruments were evalua…

AdultCross-Cultural ComparisonMalemedicine.medical_specialtyPsychometricsPsychometricsConcurrent validityMedicine (miscellaneous)Poison controlTest validityPersonality AssessmentGermanGermanymental disordersmedicineHumansPsychiatryGeneral PsychologySubstance dependenceReproducibility of ResultsMiddle Agedmedicine.diseaseCross-cultural studieslanguage.human_languageEuropeInter-rater reliabilityAlcoholismlanguageFemalePsychologyJournal of studies on alcohol
researchProduct

No association of alcohol dependence with a NMDA-receptor 2B gene variant

2003

Brain Chemistrymedicine.medical_specialtyLRP1BAlcohol dependenceGenetic variantsBiologyReceptors N-Methyl-D-AspartateMolecular biologyAlcoholismCellular and Molecular NeurosciencePsychiatry and Mental healthEndocrinologyInternal medicineNMDA receptor 2Bmedicinebiology.proteinHumansNMDA receptorGRIN2A5-HT5A receptorMolecular BiologyMolecular Psychiatry
researchProduct

EPA-0703 – Performance of the hamilton depression rating subscales to predict antidepressant treatment response in the early course of treatment

2014

Early improvement ( EI ), i.e. a symptom reduction from baseline of at least 20% after 2 weeks, has been proven to be a clinically useful predictor for later treatment outcome. In most studies EI is identified by using the sum score of the Hamilton Depression Rating Scale (HAMD). Several unidimensional subscales of the HAMD exist, which have proven to be an economic measure of treatment change. Their ability to detect onset of improvement in comparison to the full HAMD has not been researched yet. The present study investigated in patients with major depression (MD) (1) whether the HAMD subscales are a valid and economic option to predict antidepressant treatment response in the early cours…

Predictive validityPsychiatry and Mental healthReceiver operating characteristicRating scaleMirtazapineHamdmedicineAntidepressantPsychologyParoxetineDepression (differential diagnoses)medicine.drugClinical psychologyEuropean Psychiatry
researchProduct

Three dimensions of depression in patients with acute psychotic disorders: A replication study

1999

Depressive symptoms in psychotic disorders are of high relevance but seem to be heterogeneous when assessed with a standard rating scale. The present analysis is a replication study on the dimensionality of the Bech-Rafaelsen Melancholia Scale (BRMES) in acutely psychotic patients with substantial depression defined according to a functional approach across the nosological borders of schizophrenia with major affective symptoms, schizoaffective disorder, depressed subtype, and major depression with psychotic features. The baseline data of 123 patients participating in a multicenter pharmacological trial were evaluated with structural equation models. A previously reported three-dimensional m…

AdultMalePsychosismedicine.medical_specialtyAdolescentPsychometricslcsh:RC435-571Schizoaffective disorderSeverity of Illness IndexStructural equation modelingRating scalelcsh:PsychiatryMelancholiamedicineHumansPsychiatryAgedPsychiatric Status Rating ScalesDepressive Disorder MajorReproducibility of ResultsMiddle Agedmedicine.diseasePsychiatry and Mental healthClinical PsychologyPsychotic DisordersSchizophreniaAcute DiseaseSchizophreniaFemaleSchizophrenic PsychologyPsychomotor Disordersmedicine.symptomFactor Analysis StatisticalPsychologyPsychomotor disorderClinical psychologyComprehensive Psychiatry
researchProduct

Syndrome profiles in alcoholism and panic disorder with or without agoraphobia

2002

It is proposed that alcoholism and panic disorder/agoraphobia demonstrate in part common genetic and environmental origins. Shared subthreshold symptom patterns in the parents' generation could confirm the proposed genetic role in alcoholism and panic disorder/agoraphobia, even if the parents do not fulfil the diagnostic criteria for a primary psychiatric diagnosis. This is the first family study of exploratively analyzing subthreshold symptoms in both disorders. The authors investigated families with panic disorder/agoraphobia and/or alcoholism with the Munich-Composite International Diagnostic Interview (M-CIDI). We documented the diagnoses according to Diagnostic and Statistical Manual o…

PharmacologyProbandmedicine.medical_specialtyAddictionmedia_common.quotation_subjectPanic disorderPanicICD-10medicine.diseasebehavioral disciplines and activitieshumanitiesmental disordersmedicineAnxietymedicine.symptomPsychologyPsychiatryBiological PsychiatryAnxiety disordermedia_commonClinical psychologyAgoraphobiaProgress in Neuro-Psychopharmacology and Biological Psychiatry
researchProduct

Association study of affective disorders with genetic polymorphisms of monoamine oxidases

2000

Introduction: Monoamine oxidases (MAO) catalyze the oxidative deamination of monoamines like norepinephrine, serotonin and dopamine. The existing MAOs (A and B) have distinct although partially overlapping biological functions and distributions in the brain. MAO A is mainly expressed in catecholaminergic neurons. Thirty-fold differences in enzyme activity of MAO A can be found in cultured cells from different individuals suggesting a genetic determination of enzyme activity. Indeed, a point mutation in the coding region of the gene which creates a restriction site for Fnu4HI alters the activity. Moreover, the pharmacological inhibition of monoamine oxidase A activity is one of the most effe…

Pharmacologymedicine.medical_specialtybiologybusiness.industrymedicine.diseaseGenotype frequencySubstance abusePsychiatry and Mental healthMonoamine neurotransmitterEndocrinologyNeurologyMood disordersInternal medicineGenetic variationmedicinebiology.proteinPharmacology (medical)Neurology (clinical)Monoamine oxidase BAlleleMonoamine oxidase AbusinessBiological PsychiatryEuropean Neuropsychopharmacology
researchProduct

Mirtazapine compared with paroxetine in major depression.

2000

Background: The aim was to compare the efficacy and tolerability of mirtazapine with those of paroxetine. Method: 275 outpatients with a diagnosis of major depressive episode (DSM-IV) and a score ≥ 18 on the 17-item Hamilton Rating Scale for Depression (HAM-D-17) were randomly assigned to 6 weeks of treatment with mirtazapine (15-45 mg/day) or paroxetine (20-40 mg/day). Efficacy was assessed by the HAM-D-17, Hamilton Rating Scale for Anxiety (HAM-A), and Clinical Global Impressions scales (Severity and Improvement), and analyses were performed on the intent-to-treat sample (127 mirtazapine-treated patients and 123 paroxetine-treated patients). Results: Mean daily doses were 32.7 mg of mirta…

AdultMalemedicine.medical_specialtyNauseaMirtazapineMirtazapineMianserinAntidepressive Agents TricyclicSeverity of Illness IndexDrug Administration Schedulelaw.inventionRandomized controlled trialDouble-Blind MethodlawInternal medicinemedicineAmbulatory CareHumansPsychiatryMajor depressive episodeAgedPsychiatric Status Rating ScalesDepressive DisorderHamilton Rating Scale for DepressionMiddle AgedParoxetinePsychiatry and Mental healthParoxetineTreatment OutcomeTolerabilityAnxietyFemalemedicine.symptomPsychologymedicine.drugThe Journal of clinical psychiatry
researchProduct

Effects of Interrater Reliability of Psychopathologic Assessment on Power and Sample Size Calculations in Clinical Trials

2002

Although rater training is increasingly used to improve the quality of the investigated outcome parameters, the reliability of assessments is not perfect. Thus, empirical reliability estimates should be used instead of theoretically assumed perfect reliability. Implications of the reliability of psychiatric assessments for sample size and power calculations in clinical trials are presented. The theoretical basis of sample size and power calculations using empirical reliability scores is delineated. Examples from contemporary research on schizophrenia and depression are used to illustrate several implications for study design and interpretation of results. The tremendous impact of the lack o…

Observer VariationEstimationClinical Trials as TopicPsychopathologybusiness.industrymedia_common.quotation_subjectClinical trialPsychiatry and Mental healthPower analysisInter-rater reliabilitySample size determinationSample SizeStatisticsHumansPharmacology (medical)Quality (business)PsychologybusinessQuality assuranceReliability (statistics)media_commonJournal of Clinical Psychopharmacology
researchProduct

Combination treatment with nefazodone and cognitive-behavioral therapy for relapse prevention in alcohol-dependent men: a randomized controlled study.

2004

Background This study evaluated the serotonergic antidepressant nefazodone versus placebo and specific cognitive-behavioral therapy (CBT) versus nondirective group counseling (GC) for relapse prevention in alcohol dependence in a large prospective, randomized, and placebo-controlled double-blind study at 3 German university centers. Method 242 male patients fulfilling at least 5 criteria for alcohol dependence according to DSM-IV and ICD-10 were eligible, after detoxification, for one of the following treatment combinations: nefazodone + CBT, nefazodone + GC, placebo + CBT, and placebo + GC. Either nefazodone or placebo was administered throughout the evaluation period of 15 months. Either …

AdultCounselingMalemedicine.medical_specialtymedicine.medical_treatmentRelapse preventionPlaceboPiperazineslaw.inventionGroup psychotherapyPlacebosRandomized controlled triallawInternal medicinemedicineSecondary PreventionHumansDiagnosis Computer-AssistedPsychiatryPsychiatric Status Rating ScalesCognitive Behavioral TherapyAlcohol dependenceTriazolesCombined Modality TherapyClinical trialCognitive behavioral therapyPsychiatry and Mental healthAlcoholismTreatment OutcomePsychologyNefazodonemedicine.drugThe Journal of clinical psychiatry
researchProduct

Vitamin B12 and hepatic enzyme serum levels correlate in male alcohol-dependent patients.

2001

- Vitamin B12 serum levels and markers for alcohol consumption were determined in 80 male alcohol-dependent patients. Spearman correlation coefficients (r(S)) were calculated. Significant positive correlations between vitamin B12 and hepatic enzyme values were found (gamma-glutamyltransferase: r(S) = 0.58; alanine aminotransferase: r(S) = 0.43; aspartate aminotransferase: r(S) = 0.47; glutamate dehydrogenase: r(S) = 0.43; all P:0.001). Therefore, for a proper interpretation of vitamin B12 levels, it may be clinically relevant to take markers of hepatocellular damage into account.

AdultErythrocyte IndicesMalemedicine.medical_specialtyCarbohydrate deficient transferrinAspartate transaminaseStatistics NonparametricGlutamate DehydrogenaseInternal medicineBlood plasmamedicineHumansCyanocobalaminVitamin B12Aspartate AminotransferasesLiver Diseases AlcoholicRetrospective StudiesbiologyGlutamate dehydrogenaseTransferrinnutritional and metabolic diseasesAlanine TransaminaseGeneral Medicinegamma-GlutamyltransferaseMiddle AgedAlcoholismVitamin B 12EndocrinologyAlanine transaminaseLiverToxicitybiology.proteinBiomarkersAlcohol and alcoholism (Oxford, Oxfordshire)
researchProduct

Medikamente zur Behandlung von Persönlichkeitsstörungen

1998

Die Therapie von Personlichkeitsstorungen war lange Zeit ausschlieslich eine Domane psychotherapeutischer Interventionen. Mittlerweile existieren einige kontrollierte Studien auch zum Einsatz von Psychopharmaka bei Personlichkeitsstorungen Die Ergebnisse sind aber fur allgemeine Empfehlungen noch zu wenig abgesichert. Die Diagnose von Personlichkeitsstorungen (z. B. Achse-Il-Storungen nach DSM-IV) ist fehleranfallig. Die diagnostischen Kategorien sind uneinheitlich und derzeit noch im Flus; selbst strukturierte Interviews erfahrener Untersucher zeigen nur begrenzte Verlaslichkeit. Wichtig ist die Erfassung und — wenn moglich — Abgrenzung von gleichzeitig vorhandenen Achse-I-Storungen nach D…

researchProduct

Analysis of genetic variations of protein tyrosine kinase fyn and their association with alcohol dependence in two independent cohorts.

2003

Abstract Background Decreased sensitivity to and increased tolerance for the effects of alcohol is a phenotype, which was shown to be associated with an increased risk for alcoholism in humans and was observed in protein tyrosine kinase (PTK) fyn knockout mice. Methods We performed an association study of genetic variations of PTK fyn in 430 alcohol-dependent patients and 365 unrelated control subjects from two independent samples. Results In a combined analysis, we found an association of alcohol dependence with the single nucleotide polymorphism (SNP) T137346C in the 5′ untranslated region (UTR) of the gene. A relevant association could be excluded for the remaining two informative SNPs. …

AdultMaleThreonineLinkage disequilibriumGenotypeGlycineSingle-nucleotide polymorphismBiologyProto-Oncogene Proteins c-fynPolymorphism Single NucleotideCohort StudiesFYNGene FrequencyProto-Oncogene ProteinsGenotypeSNPHumansCysteineAlleleBiological PsychiatryGeneticsAlanineChi-Square DistributionAlcohol dependenceGenetic VariationMiddle AgedAlcoholismCase-Control StudiesFemale5' Untranslated RegionsTyrosine kinaseBiological psychiatry
researchProduct

The Primary Care Evaluation of Mental Disorders (PRIME-MD), German version: a comparison with the CIDI

2000

There is a need for the development and evaluation of diagnostic instruments suitable for daily use in primary care offices that can improve recognition rates of psychopathology. The objective of this study is the comparison of the German version of the Primary Care Evaluation of Mental Disorders (PRIME-MD), a short structured diagnostic instrument, with the Composite International Diagnostic Interview (CIDI) and to gather some information on the usefulness of the PRIME-MD. Seven hundred and four patients were assessed three times, once using the physician's clinical judgement, subsequently, administering the PRIME-MD, DSM-IV version and finally, with the CIDI. The CIDI was administered on …

Hospitals PsychiatricMalemedicine.medical_specialtyPsychometricsPsychometricsTest validitySensitivity and SpecificityPredictive Value of TestsGermanyHumansMass ScreeningMedicinePsychiatryBiological PsychiatryPsychiatric Status Rating ScalesPrimary Health Carebusiness.industryMental Disordersmedicine.diseaseCIDIPsychiatry and Mental healthEating disordersMood disordersStructured interviewAnxietyFemalemedicine.symptombusinessPsychopathologyClinical psychologyJournal of Psychiatric Research
researchProduct

Association of aMAOAgene variant with generalized anxiety disorder, but not with panic disorder or major depression

2001

This study was conducted to detect a possible association of a T941G single nucleotide polymorphism (SNP) in the monoamine oxidase A (MAOA) gene with generalized anxiety disorder (GAD), panic disorder (PD), or major depression (MD). Fifty GAD patients (34 females and 16 males), 38 PD patients (21 females and 17 males), and 108 MD patients (80 females and 28 males) were included. The comparison group consisted of 276 (132 females and 144 males) unrelated healthy individuals. The 941T allele was over-represented in patients suffering from GAD (chi(2) = 6.757; df = 1; P < 0.01, not corrected for multiple testing) when compared to healthy volunteers. No association was observed in MD or PD. Thi…

medicine.medical_specialtyGeneralized anxiety disorderbiologybusiness.industryPanic disorderPanicSingle-nucleotide polymorphismmedicine.diseaseCellular and Molecular NeurosciencePsychiatry and Mental healthInternal medicinemedicinebiology.proteinAnxietymedicine.symptomMonoamine oxidase AbusinessAllele frequencyGenetics (clinical)Anxiety disorderAmerican Journal of Medical Genetics Part B: Neuropsychiatric Genetics
researchProduct

Medikamente zur Phasenprophylaxe affektiver Psychosen und zur Behandlung manischer Syndrome

1998

Folgende Substanzgruppen sind in der Therapie manischer Syndrome und/oder in der Phasenprophylaxe affektiver Storungen etabliert (Im folgenden werden die Begriffe affektive bzw. schizoaffektive „Storung“ bzw. „Psychose“ weitgehend synonym verwendet.)

researchProduct

No Association Between the Dopamine D2 Receptor Taq I A1 Allele and Earlier Age of Onset of Alcohol Dependence According to Different Specified Crite…

2001

BACKGROUND: The presence of the A1 allele of the dopamine D2 receptor TaqI restriction fragment length polymorphism has been reported to be associated with an earlier age of onset of alcohol dependence as a marker for severity. METHODS: We tested this hypothesis with special regard to the definition of the age of onset of alcoholism in 243 patients with alcohol dependence, according to DSM-IV criteria assessed by the standardized interview Munchner Composite International Diagnostic Interview (M-CIDI), consecutively admitted for detoxification. Additionally, the Addiction Severity Index (ASI) was performed. The TaqIA polymorphism was amplified by polymerase chain reaction (PCR), and the PCR…

Geneticsmedicine.medical_specialtyTaqIAlcohol dependenceMedicine (miscellaneous)Binge drinkingToxicologyPsychiatry and Mental healthchemistry.chemical_compoundchemistryPolymorphism (computer science)Internal medicinemedicineAlleleAge of onsetRestriction fragment length polymorphismPsychologyAllele frequencyAlcoholism: Clinical and Experimental Research
researchProduct

Symptom-Triggered versus Standard Chlormethiazole Treatment of Inpatient Alcohol Withdrawal: Clinical Implications from a Chart Analysis

2003

To evaluate clinical effectiveness and safety of 2 different detoxification treatment protocols, a chart analysis of hospital inpatients consecutively admitted for alcohol withdrawal during one year was undertaken. Records of 33 patients receiving symptom-triggered treatment (using a modified version of the revised Clinical Institute Withdrawal Assessment for Alcohol Scale) were compared with those of patients treated by applying a fixed-dose regimen (n = 32). Patients (45.3 ± 9.8 years, 21% female) of both groups were comparable regarding illness severity, epidemiologic parameters as well as complications during the observed treatment period. Under symptom-triggered therapy, chlormethiazol…

AdultMalemedicine.medical_specialtyHealth (social science)Clinical effectivenessTreatment outcomeMedicine (miscellaneous)AlcoholStatistics Nonparametricchemistry.chemical_compoundChartDetoxificationHumansMedicineChlormethiazoleRetrospective StudiesInpatientsChi-Square Distributionbusiness.industryRetrospective cohort studyMiddle AgedSubstance Withdrawal SyndromeAlcoholismPsychiatry and Mental healthTreatment OutcomechemistryAnesthesiaEmergency medicineFemalebusinessChlormethiazoleChi-squared distributionEuropean Addiction Research
researchProduct

The HTR1B 861GC receptor polymorphism among patients suffering from alcoholism, major depression, anxiety disorders and narcolepsy.

2000

Abstract The HTR1B receptor gene has been linked to antisocial alcoholism in a Finnish population and an American Indian tribe [Lappalainen et al., Arch. Gen. Psychiatry, 55 (1998) 989]. Using a candidate gene approach, we genotyped 209 patients with alcoholism, 108 patients with major depression, 32 patients with panic disorder, 50 patients with generalized anxiety disorder, 58 patients with narcolepsy and 74 healthy volunteers for the HTR1B 861G>C polymorphism. There was a higher frequency of the HTR1B 861G alleles among the alcohol-dependent patients as compared to the control subjects (χ 2 =4.02, d.f.=2, P =0.04). However, the association resulted from higher frequencies of the opposite…

AdultMaleRiskCandidate genemedicine.medical_specialtyGeneralized anxiety disorderGenotypeInternal medicineGermanymedicineHumansPsychiatryTemperamentBiological PsychiatryPsychiatric geneticsAllelesNarcolepsyDepressive Disorder MajorPolymorphism GeneticPanic disorderPanicmedicine.diseaseAnxiety DisordersPsychiatry and Mental healthAlcoholismPhenotypeCase-Control StudiesReceptors SerotoninReceptor Serotonin 5-HT1BAnxietyPanic DisorderChromosomes Human Pair 6Femalemedicine.symptomPsychologyAnxiety disorderNarcolepsyPsychiatry research
researchProduct

Moderate and severe depression

2000

Background: Despite its importance, no distinction between moderate and severe depression using the Montgomery–Asberg Depression Rating Scale (MADRS) based on a direct comparison with the Hamilton Depression Rating Scale (HAMD-17) is available. Methods: HAMD-17 and MADRS ratings from N=40 at least moderately depressed inpatients with major depression (DSM-III-R) were analyzed. Linear and non-parametric correlations were computed and a MADRS cut-off score for severe depression using an HAMD-17 score of at least 28 points as reference was estimated. Results: HAMD-17 and MADRS mean scores were 24.6±4.3 and 32.6±5.0 points, respectively. Linear correlation of both scores was r=0.70 (P<0.0005). …

medicine.medical_specialtyPsychometricsPsychiatry and Mental healthClinical PsychologyRating scaleSample size determinationClinical investigationPredictive value of testsMontgomery–Åsberg Depression Rating ScaleSeverity of illnessmedicineLinear correlationPsychiatryPsychologyClinical psychologyJournal of Affective Disorders
researchProduct

GRIN1 locus may modify the susceptibility to seizures during alcohol withdrawal

2005

N-Methyl-D-aspartate (NMDA) receptors, members of the glutamate receptor channel superfamily, are generally inhibited by alcohol. The expression and alternative splicing of the obligatory NR1 subunit is altered by alcohol exposure, emphasizing the involvement of the NR1 subunit, which is coded by the GRIN1 gene, in alcohol-mediated effects. We performed an association study in patients with alcohol dependence with the GRIN1 locus. Two independent case control samples consisting of a total of 442 alcohol-dependent patients and 442 unrelated controls were included. There was no overall difference in allele or genotype frequency between patients and controls. However, the 2108A allele and A-co…

Geneticsmedicine.medical_specialtyDelirium tremensbiologyAlcohol dependenceGRIN1Locus (genetics)medicine.diseaseGenotype frequencyCellular and Molecular NeurosciencePsychiatry and Mental healthEpilepsyEndocrinologyInternal medicineGenotypemedicinebiology.proteinAlleleGenetics (clinical)American Journal of Medical Genetics Part B: Neuropsychiatric Genetics
researchProduct

Differentiating moderate and severe depression using the Montgomery–Åsberg depression rating scale (MADRS)

2003

MADRS cut-off scores for moderate and severe depression were estimated in relation to the Hamilton Depression Rating Scale (HAMD(17)) and the Clinical Global Impressions Scale (CGI).HAMD(17), MADRS, and CGI ratings from patients with major depression (DSM-IV) were analyzed (N=85). Receiver operating characteristics (ROC) curves were applied.Mean age was 51.4+/-14.5 years, 69% were female. Mean MADRS scores were 23.4+/-13.2, HAMD(17), MADRS, and CGI scores were highly correlated (r0.85; P0.0001). Best separation between moderate and severe depression according to CGI criteria was achieved with a MADRS score of 31 (sensitivity 93.5%, specificity 83.3%).Studies to validate severity gradations …

AdultMalemedicine.medical_specialtyPsychometricsTest validitySeverity of Illness IndexDiagnosis DifferentialReference ValuesRating scalemental disordersSeverity of illnessmedicineHumansPsychiatryDepression (differential diagnoses)AgedDepressive DisorderReceiver operating characteristicMiddle AgedhumanitiesDiagnostic and Statistical Manual of Mental DisordersPsychiatry and Mental healthClinical PsychologyMontgomery–Åsberg Depression Rating ScaleFemaleMental Status SchedulePsychologyPsychopathologyJournal of Affective Disorders
researchProduct

Response to treatment in minor and major depression: results of a double-blind comparative study with paroxetine and maprotiline.

1997

Several concepts of minor depression in the sense of acute but less severe symptomatology than major depression have been proposed in the literature, but currently none of them is generally accepted. For the treatment of these conditions, only few recommendations based on empirical data are available. We conducted a randomized double-blind multicentre study in depressed outpatients comparing paroxetine and maprotiline in both patients with minor (n = 245) and major depression (n = 298). For the diagnosis, Research Diagnostic Criteria were used in a modified version. Two response criteria were applied: a reduction of 50% or more in total HAMD-17 scores from baseline (criterion 1), and a redu…

AdultMalemedicine.medical_specialtyAdolescentPersonality InventoryResearch Diagnostic CriteriaPlaceboSeverity of Illness IndexXerostomiaDouble blindPlacebosPharmacotherapyDouble-Blind MethodInternal medicinemedicineHumansMaprotilinePsychiatryDepression (differential diagnoses)AgedPsychiatric Status Rating ScalesDepressive DisorderMiddle AgedParoxetinePsychiatry and Mental healthClinical PsychologyParoxetineTreatment OutcomeMaprotilineAntidepressantFemalePsychologymedicine.drugJournal of affective disorders
researchProduct

Addition of Low-Dose Fluvoxamine to Low-Dose Clozapine Monotherapy in Schizophrenia: Drug Monitoring and Tolerability Data from a Prospective Clinica…

1999

Combining fluvoxamine and clozapine may be a strategy to improve therapeutic effects on negative symptoms in schizophrenic patients. Fluvoxamine, however, markedly inhibits the metabolism of clozapine, and hazardous side effects may result. This study prospectively investigated the safety and tolerability of an add-on therapy with fluvoxamine to a clozapine monotherapy in schizophrenic patients. Sixteen schizophrenic patients received 50 mg fluvoxamine as a comedication after having reached steady-state conditions under clozapine monotherapy. Patients were monitored for subjective adverse events, laboratory parameters, EEG and ECG recordings, orthostatic hypotension and their psychopatholog…

AdultMaleAdolescentMatched-Pair AnalysisFluvoxamineDrug Administration ScheduleOrthostatic vital signsmedicineHumansDrug InteractionsPharmacology (medical)Prospective StudiesAdverse effectClozapineClozapineTherapeutic effectGeneral MedicineMiddle AgedDrug interactionPsychiatry and Mental healthTreatment OutcomeTolerabilityFluvoxamineAnesthesiaSchizophreniaAntidepressive Agents Second-GenerationDrug Therapy CombinationFemaleDrug MonitoringPsychologyReuptake inhibitorSelective Serotonin Reuptake InhibitorsAntipsychotic Agentsmedicine.drugPharmacopsychiatry
researchProduct

Cue exposure in alcohol dependent patients: preliminary evidence for different types of cue reactivity.

2000

Craving is considered to be an important phenomenon in addictive behaviours. However, there is still an unresolved debate on what craving for alcohol means, how it is best measured and which clinical and therapeutical consequences its presence or absence may imply. Cue reactivity paradigms have been developed to elicit craving under standardized experimental conditions. Here we present preliminary results characterizing alcohol-dependent patients with regard to subjective and psychophysiological aspects of exposure to alcohol-associated cues in a cue reactivity paradigm. Thirty-six patients fulfilling at least 5 criteria of alcohol dependence according to DSM-IV criteria were studied after …

AdultMalemedicine.medical_specialtyNeurologyCue exposuremedia_common.quotation_subjectAlcoholCravingAudiologychemistry.chemical_compoundElectrocardiographyConditioning PsychologicalmedicineHumansPsychiatryBiological Psychiatrymedia_commonElectromyographyAddictionAlcohol dependenceGalvanic Skin ResponseMiddle AgedSubstance Withdrawal SyndromePsychiatry and Mental healthAlcoholismNeurologychemistryCue reactivityOdorantsAnxietyNeurology (clinical)medicine.symptomPsychologyPhotic StimulationJournal of neural transmission (Vienna, Austria : 1996)
researchProduct

Minimum effective dose for antidepressants - an obligatory requirement for antidepressant drug evaluation?

1996

Extensive clinical trials are required for registration and approval of new antidepressants in most countries including the requirement that a minimal effective dose should be determined. The rationale for this requirement is to avoid the use of unnecessarily high doses. The implication is that for every antidepressant, a dose exists that serves as a threshold, below which all doses are not effective or are clearly less effective in treating a major depressive episode. Dose titration and fixed dose studies are used to determine the minimal effective dose, but both strategies have limitations and often do not allow definite establishment of a clear-cut minimal effective dose. The effort of e…

Drugmedicine.medical_specialtymedia_common.quotation_subjectComorbidityPharmacologyPharmacokineticsmedicineHigh dosesHumansEthics MedicalPharmacology (medical)Intensive care medicineMajor depressive episodemedia_commonClinical Trials as TopicDepressive DisorderDose-Response Relationship Drugbusiness.industryConfounding Factors EpidemiologicEffective dose (pharmacology)Antidepressive AgentsClinical trialPsychiatry and Mental healthSample size determinationAntidepressantmedicine.symptombusinessInternational Clinical Psychopharmacology
researchProduct

Risperidone Versus Haloperidol and Amitriptyline in the Treatment of Patients With a Combined Psychotic and Depressive Syndrome

1998

In a multicenter, double-blind, parallel group trial, the efficacy of risperidone (RIS) was compared with a combination of haloperidol and amitriptyline (HAL/AMI) over 6 weeks in patients with coexisting psychotic and depressive symptoms with either a schizoaffective disorder, depressive type, a major depression with psychotic features, or a nonresidual schizophrenia with major depressive symptoms according to DSM-III-R criteria. A total of 123 patients (62 RIS; 61 HAL/AMI) were included; the mean daily dosage at endpoint was 6.9 mg RIS versus 9 mg HAL combined with 180 mg AMI. Efficacy results for those 98 patients (47 RIS; 51 HAL/AMI) who completed at least 3 weeks of double-blind treatme…

AdultMalemedicine.medical_specialtyAdolescentAmitriptylineSchizoaffective disorderAntidepressive Agents Tricycliclaw.inventionDouble-Blind MethodExtrapyramidal symptomsRandomized controlled triallawInternal medicineBrief Psychiatric Rating ScalemedicineHaloperidolHumansPharmacology (medical)AmitriptylinePsychiatryAgedPsychiatric Status Rating ScalesDepressive DisorderRisperidoneMiddle AgedRisperidonemedicine.diseasePsychiatry and Mental healthPsychotic DisordersSchizophreniaHaloperidolFemalemedicine.symptomPsychologyAntipsychotic Agentsmedicine.drugJournal of Clinical Psychopharmacology
researchProduct

Tyrosine hydroxylase Val-81-Met polymorphism associated with early-onset alcoholism

2005

The present study examined the association of the Tyrosine hydroxylase Val-81-Met polymorphism with alcohol dependence. One hundred and fifty-nine patients in a psychiatric unit with alcohol dependence were genotyped as well as 92 healthy volunteers. The Val allele was more frequent in patients with alcohol dependence (69.5%) than in controls (62.5%). This effect was largely due to the association with early-onset alcoholism (77.8%), whereas no difference was noted between late-onset patients and controls. Our results suggest a role for tyrosine hydroxylase in early-onset alcoholism.

Adultmedicine.medical_specialtyGenotypeTyrosine 3-MonooxygenaseMutation MissensePolymerase Chain ReactionPolymorphism Single Nucleotidechemistry.chemical_compoundMethionineReference ValuesInternal medicineGenotypeGeneticsHumansMedicineMissense mutationAge of OnsetAlleleBiological PsychiatryGenetics (clinical)DNA PrimersEarly onsetMethionineBase SequenceTyrosine hydroxylasebusiness.industryAlcohol dependenceValineAlcoholismPsychiatry and Mental healthEndocrinologychemistryAge of onsetbusinessPolymorphism Restriction Fragment LengthPsychiatric Genetics
researchProduct

Activity of the adenylyl cyclase in lymphocytes of male alcoholic patients is state dependent.

1998

A decreased basal and/or stimulated activity of the G-protein/adenylyl cyclase (AC) system in peripheral blood cells has been proposed to represent a trait marker for alcoholism. However, AC activity may underlie state-dependent changes, which may impair a proper interpretation of AC activity measurements. Our study examined systematically the AC activity in peripheral lymphocytes of 73 male alcohol-dependent patients (according to DSM-IV criteria) at three different time points of measurement during the clinical course of detoxification (day 0 = at admission, while still ethanol-affected; day 2 = at the presumed peak of withdrawal symptoms; day E = after detoxification). Basal and stimulat…

AdultMalemedicine.medical_specialtyLymphocyteGTPgammaSMedicine (miscellaneous)ToxicologyAdenylyl cyclaseAlcohol Withdrawal Deliriumchemistry.chemical_compoundBasal (phylogenetics)Reference ValuesInternal medicineDetoxificationmedicineHumansLymphocytesAgedForskolinbusiness.industryMiddle AgedPeripheralPsychiatry and Mental healthAlcoholismmedicine.anatomical_structureEndocrinologychemistryToxicitybusinessBiomarkersAdenylyl CyclasesAlcoholism, clinical and experimental research
researchProduct

Reliability and validity of the form 90 interview.

2004

&lt;i&gt;Objective:&lt;/i&gt; Alcohol consumption is a central variable in substance abuse research and treatment. The study reports the psychometric characteristics of the German version of the Form 90 interview for the assessment of recent alcohol consumption. &lt;i&gt;Method:&lt;/i&gt; Reliability was evaluated in a test-retest study (7 days) with 30 consecutively admitted psychiatric inpatients with alcohol dependence. Validity of Form 90 was assessed with a second sample of 60 alcohol-dependent inpatients. &lt;i&gt;Results:&lt;/i&gt; Form 90 demonstrated good to excellent retest reliability for the central variables of alcohol consumption. Retest reliability Pearson correlation coeffic…

AdultMaleHealth (social science)Alcohol DrinkingPsychometricsIntraclass correlationSubstance-Related DisordersTemperanceStatistics as TopicMedicine (miscellaneous)AlcoholComorbidityMedical RecordsAlcohol Withdrawal Deliriumchemistry.chemical_compoundsymbols.namesakeGermanyInterview PsychologicalmedicineHumansReliability (statistics)Mental DisordersAlcohol dependenceReproducibility of ResultsMiddle Agedmedicine.diseaseConfidence intervalPearson product-moment correlation coefficientSubstance abuseHospitalizationPsychiatry and Mental healthAlcoholismchemistryStructured interviewsymbolsPatient ComplianceFemalePsychologyClinical psychologyFollow-Up StudiesEuropean addiction research
researchProduct

The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depr…

2004

The catechol-O-methyltransferase (COMT) is a major degrading enzyme in the metabolic pathways of catecholaminergic neurotransmitters such as dopamine and norepinephrine. This study investigated whether the functionally relevant Val(108/158)Met gene variant is associated with differential antidepressant response to mirtazapine and/or paroxetine in 102 patients with major depression (DSM-IV criteria) participating in a randomized clinical trial with both drugs. In patients treated with mirtazapine, but not paroxetine, allelic variations in the COMT gene were associated with differential response. COMT(VAL/VAL) and COMT(VAL/MET) genotype carriers showed a better response than COMT(MET/MET)-bea…

AdultMaleTime FactorsMirtazapineMirtazapineMianserinPharmacologyCatechol O-Methyltransferaselaw.inventionMethionineRandomized controlled triallawDopamineGenotypeGeneticsmedicineHumansPharmacologyDepressive Disorder MajorCatechol-O-methyl transferasePolymorphism Geneticbusiness.industryHamilton Rating Scale for DepressionValineMiddle AgedParoxetineParoxetineMolecular MedicineAntidepressantFemalebusinessmedicine.drugThe pharmacogenomics journal
researchProduct

Serotonin dysfunction syndromes: a functional common denominator for classification of depression, anxiety, and obsessive-compulsive disorder.

1993

Psychiatric Status Rating Scalesmedicine.medical_specialtyDepressive DisorderObsessive-Compulsive DisorderSerotoninCommon denominatormedicine.diseaseAnxiety DisordersSerotonin Receptor AgonistsPsychiatry and Mental healthObsessive compulsiveReceptors SerotoninPsychiatric status rating scalesmedicineAnxietyHumansPharmacology (medical)SerotoninSerotonin Antagonistsmedicine.symptomPsychiatryPsychologyAnxiety disorderDepression (differential diagnoses)Selective Serotonin Reuptake InhibitorsInternational clinical psychopharmacology
researchProduct

The TPH intron 7 A218C polymorphism and TCI dimension scores in alcohol-dependent patients: hints to nonspecific psychopathology

2004

Abstract Aims A linkage of certain alleles of the tryptophan hydroxylase (TPH) intron 7 A218C polymorphism to suicidality and antisocial behaviour has been described. The aim of our study was to find any association between dimensions of the Temperament and Character Inventory (TCI) indicating impulsivity and the TPH polymorphism alleles in unselected alcohol-dependent patients and age-matched controls. Methods We examined 159 alcohol-dependent patients and 161 controls with the TCI and genotyped them for the TPH intron 7 A218C polymorphism alleles. Results Although homozygous TPH genotypes were found more often in alcohol-dependent patients than in controls, an association between TCI dime…

AdultMaleHeterozygoteendocrine systemmedicine.medical_specialtyGenotypeMedicine (miscellaneous)Tryptophan HydroxylaseToxicologyImpulsivityGene FrequencyInternal medicineGenotypemedicineHumansAlleleTemperamentPsychiatric geneticsPolymorphism GeneticHomozygoteTryptophan hydroxylasemedicine.diseaseIntronsAlcoholismPsychiatry and Mental healthClinical PsychologyEndocrinologyCase-Control StudiesImpulsive BehaviorHarm avoidanceFemaleTemperament and Character Inventorymedicine.symptomPsychologyPsychopathologyClinical psychologyAddictive Behaviors
researchProduct

Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depressi…

2003

OBJECTIVE Current clinical knowledge holds that antidepressants have a delayed onset of efficacy. However, the delayed onset hypothesis has been questioned recently by survival analytical approaches. We aimed to test whether early improvement under antidepressant treatment is a clinically useful predictor of later stable response and remission. METHOD We analyzed data from a randomized double-blind controlled trial with mirtazapine and paroxetine in patients with major depression (DSM-IV). Improvement was defined as a 17-item Hamilton Rating Scale for Depression (HAM-D-17) score reduction of > or = 20%. Stable response was defined as > or = 50% HAM-D-17 score reduction at week 4 and week 6,…

AdultMalemedicine.medical_specialtyAdolescentMirtazapineMirtazapineMianserinAntidepressive Agents TricyclicDrug Administration Schedulelaw.inventionRandomized controlled trialDouble-Blind MethodlawInternal medicinemedicineAmbulatory CareHumansPsychiatrySurvival analysisDepression (differential diagnoses)AgedPsychiatric Status Rating ScalesDepressive DisorderHamilton Rating Scale for DepressionMiddle AgedPrognosisParoxetineSurvival AnalysisClinical trialPsychiatry and Mental healthParoxetineTreatment OutcomeAntidepressantDrug Therapy CombinationFemalePsychologySelective Serotonin Reuptake Inhibitorsmedicine.drug
researchProduct

Neuropsychological status of alcohol-dependent patients: increased performance through goal-setting instructions.

2004

Aims: The effects of goal-setting instructions on neuropsychological performance of alcohol-dependent patients and control subjects were assessed. Methods: 57 alcohol-dependent patients and 59 carefully age- and education-matched healthy control subjects underwent standard neuropsychological investigation. In addition, the goal-setting paradigm was used to systematically manipulate motivation. Participants were requested to calculate simple mathematical problems repeatedly within phases of a 2-min duration receiving normal or goal setting-instructions (to increase performance in the next phase by 20%). Results: The patients demonstrated deficits in standard neuropsychological tests. Patient…

Psychomotor learningAdultMalemedicine.medical_specialtyAnalysis of VarianceObjective (goal)NeuropsychologyGeneral MedicineAudiologyMiddle AgedNeuropsychological TestsControl subjectsAlcoholismHealthy controlmedicineHumansCognitive rehabilitation therapyPsychologyCognitive impairmentGoal settingGoalsClinical psychologyAgedAlcohol and alcoholism (Oxford, Oxfordshire)
researchProduct

A double-blind study comparing paroxetine and maprotiline in depressed outpatients.

1997

A double-blind multicenter randomized parallel group study comparing paroxetine and maprotiline was carried out in a total of 544 outpatients. Included were patients with varying degrees of severity of depressive symptoms who fulfilled modified RDC criteria for either Minor or Major Depression and showed a HAMD-17 score of > or = 13. No concomitant benzodiazepine treatment was allowed. Duration of treatment was 6 weeks, after an initial wash-out period. Doses were fixed during the first 3 weeks of treatment, patients receiving either 20 mg paroxetine or 100 mg maprotiline daily. An option for dose escalation was provided for insufficient responders after 3 weeks. The weekly assessments comp…

AdultMalemedicine.drug_classDouble-Blind MethodAnticholinergicAmbulatory CareMedicineHumansPharmacology (medical)Adverse effectMaprotilinePsychiatric Status Rating ScalesBenzodiazepineDepressive Disorderbusiness.industryGeneral MedicineParoxetinePsychiatry and Mental healthParoxetineMaprotilineConcomitantAnesthesiaAntidepressantAntidepressive Agents Second-GenerationFemalebusinessReuptake inhibitormedicine.drugPharmacopsychiatry
researchProduct